Systemic Sclerosis Patients Treated With Oral Treprostinil Diethanolamine PDF Print E-mail
Wednesday, 12 June 2013 20:55
Patients with systemic sclerosis effectively absorbed oral treprostinil diethanolamine, which produced a temporal association with improved cutaneous perfusion and temperature, according to study results. In a dual-center, open-label, phase 1 study, researchers evaluated 19 patients with systemic sclerosis (SSc; mean age, 48 years; 84.2% women; 89.5% Caucasian; 53% limited SSc). Eleven patients had an active digital ulcer at baseline. Treprostinil diethanolamine sustained release (SR) was administered to patients with dose titration up to 4 mg twice daily.

Laser Doppler imaging quantified drug concentrations and perfusion, which were measured across 12 hours at 2 mg or 4 mg (or maximally tolerated) doses. Individual plasma concentration vs. time profiles using noncompartmental analysis methods determined pharmacokinetic parameters.

“Digital perfusion and skin temperature were modeled as a function of log-transformed drug concentration and other covariates by performing repeated measures analyses using random effects models,” the researchers wrote.

Sixteen patients completed the 8-week study. Approximately 3.6 hours after administration of treprostinil diethanolamine, peak plasma concentrations reached means of 1,176 pg/mL and 2,107 pg/mL for 2-mg and 4-mg doses, respectively. Overall exposure (AUC from 0 to 12 hours) was linear between doses and observed at 7,187 hr*pg/mL for 2-mg and 12,992 hr*pg/mL for 4-mg doses. Log-transformed plasma at the 4-mg dose had a positive association with perfusion (P=.015) and digital skin temperature (P=.013).

The most common adverse events were headache (89%), diarrhea (47%) and nausea (42%), which were similar to those seen with prostacyclin analogs. No serious adverse events or deaths were reported.

“Currently prostacyclin analogs are administered via intravenous or subcutaneous routes in [systemic sclerosis] patients with vascular complications,” the researchers concluded. “Our data show that oral SR formulation of treprostinil diethanolamine was effectively absorbed in patients with SSc, was associated with improved cutaneous perfusion and temperature with short-term treatment, and may provide a new therapeutic option for Raynaud’s phenomenon and peripheral vascular disease of SSc.”

Source: Helio
 
More articles :

» Natural Alternatives for Dealing With Scleroderma

In a recent article, it was noted that conventional medicine attempts to treat the symptoms of with immunosuppressant drugs, NSAIDS and , but has no cure and little advice for prevention. It was noted however, that the world of natural healing has...

» Caribbean Autoimmune Disease Summit 2011

The Caribbean Autoimmune Disease Summit 2011, is scheduled to be held this Sunday 2nd October, 2011 at the , Port of Spain, Trinidad. Hosted by the Caribbean Investor Network, the Summit aims to raise awareness of Autoimmune Diseases, their...

» Toll-like receptor 7 (TLR7)–Driven Accumulation of a Novel CD11c+ B-cell Population is Important for the Development of Autoimmunity

Anatoly V. Rubtsov, Kira Rubtsova, Aryeh Fischer, Richard T. Meehan, Joann Z. Gillis, John W. Kapple, and Philippa MarrackThe American Society of HematologyFemales are more susceptible than males to many autoimmune diseases. The processes causing...

» Lowering Salt in Your Diet

Known as sodium chloride, salt helps maintain the body's balance of fluids. Salt also functions in many foods as a preservative, by helping to prevent spoilage and keeping certain foods safe to eat. But nearly all Americans consume more salt than...

» Coping with Autoimmune Diseases

Everybody has to cope. This was the sentiment expressed by Dr. Robert Phillips at the , when he presented on Coping with Autoimmune Diseases. As Dr. Phillips discussed, each person living and dealing with an autoimmune disease would have different...

» Greater Global Cooperation and Collaboration in Scleroderma Research Required

Greater global cooperation and collaboration among Scleroderma researchers and clinicians would be all that is required to fuel a drive toward important discoveries and optimize outcomes for patients with this chronic, progressive, and often...